Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FONTII: Novel Therapies for Resistant FSGS
NCT00814255Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Dec 2008
- Primary completion
- Jun 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of adalimumab and D-galactose in focal segmental glomerulosclerosis (FSGS) (3 arms), sponsored by NYU Langone Health. Primary endpoint: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR. Started Dec 2008; status: completed.
02
Drugs
adalimumabD-galactose
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT00814255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814255.